Your browser doesn't support javascript.
loading
Application of immune checkpoint inhibitors in the treatment of small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology ; (12): 747-750, 2021.
Article in Chinese | WPRIM | ID: wpr-930033
ABSTRACT
The emergence of immune checkpoint inhibitors (ICIs) have changed the pattern of anti-tumor therapy and brought new hope to the treatment of small cell lung cancer (SCLC). Currently, ICIs are most widely studied mainly include programmed death-1/ligand-1 and cytotoxic T-lymphocyte antigen-4. Altezumab is recommended for the first-line treatment of extensive SCLC, while pebrizizumab is recommended for the third-line treatment of extensive SCLC. There has been no breakthrough in the second-line and maintenance treatment of SCLC with ICIs.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of International Oncology Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of International Oncology Year: 2021 Type: Article